Relmada Therapeutics Inc Net Assets
Relmada Therapeutics Inc net assets. Based on the latest financial reports, Relmada Therapeutics Inc (RLMD) has net assets worth $218.73 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($235.36 Million) and total liabilities ($16.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Relmada Therapeutics Inc (RLMD) balance sheet quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $218.73 Million |
| % of Total Assets | 92.93% |
| Annual Growth Rate | 98.89% |
| 5-Year Change | -58.46% |
| 10-Year Change | 1128.45% |
| Growth Volatility | 2825.96 |
Net Assets of Relmada Therapeutics Inc (2012–2025)
Net assets of Relmada Therapeutics Inc from 2012 to 2025. This chart illustrates how Relmada Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore how fast is Relmada Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Net Assets for Relmada Therapeutics Inc (2012–2025)
The table below shows the annual net assets of Relmada Therapeutics Inc from 2012 to 2025. For live market cap and overall valuation, see Relmada Therapeutics Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $86.51 Million | +143.55% |
| 2024-12-31 | $35.52 Million | -58.38% |
| 2023-12-31 | $85.36 Million | -39.22% |
| 2022-12-31 | $140.44 Million | -32.57% |
| 2021-12-31 | $208.26 Million | +97.25% |
| 2020-12-31 | $105.58 Million | -8.73% |
| 2019-12-31 | $115.68 Million | +2198.25% |
| 2018-12-31 | $-5.51 Million | -477.53% |
| 2017-12-31 | $1.46 Million | -79.26% |
| 2016-12-31 | $7.04 Million | -20.06% |
| 2015-12-31 | $8.81 Million | 0.00% |
| 2014-12-31 | $8.81 Million | +894.43% |
| 2014-06-30 | $-1.11 Million | 0.00% |
| 2013-12-31 | $-1.11 Million | -9863.70% |
| 2012-12-31 | $11.36K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Relmada Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 69825505600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Relmada Therapeutics Inc Net Assets Breakdown (December 2025)
Relmada Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $73.33K | 0.08% |
| Other Components | $784.71 Million | 907.05% |
| Total Equity | $86.51 Million | 100.00% |
Relmada Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Relmada Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Flag Chemical Industry Co Ltd
SHE:300575
|
$360.86 Million |
|
Guangdong PAK Corporation Co Ltd
SHE:300625
|
$360.93 Million |
|
Southern States Bancshares Inc
NASDAQ:SSBK
|
$361.07 Million |
|
Avidbank Holdings, Inc. Common stock
NASDAQ:AVBH
|
$361.11 Million |
|
Focus Hotmelt Co. Ltd. A
SHE:301283
|
$360.72 Million |
|
Tarczynski S.A.
WAR:TAR
|
$360.69 Million |
|
Beijing AriTime Intelligent Control Co Ltd
SHG:600560
|
$360.64 Million |
|
Dongguan Chitwing Technology Co Ltd
SHE:002855
|
$360.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Relmada Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 35,521,961 to 86,512,013, a change of 50,990,052 (143.5%).
- Net loss of 57,385,163 reduced equity.
- New share issuances of 93,637,829 increased equity.
- Other factors increased equity by 14,737,386.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-57.39 Million | -66.33% |
| Share Issuances | $93.64 Million | +108.24% |
| Other Changes | $14.74 Million | +17.04% |
| Total Change | $- | 143.55% |
Book Value vs Market Value Analysis
This analysis compares Relmada Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.57x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 953.78x to 1.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.00 | $3.44 | x |
| 2013-12-31 | $-2.27 | $3.44 | x |
| 2014-06-30 | $-0.92 | $3.44 | x |
| 2014-12-31 | $3.54 | $3.44 | x |
| 2015-12-31 | $3.55 | $3.44 | x |
| 2016-12-31 | $2.43 | $3.44 | x |
| 2017-12-31 | $0.48 | $3.44 | x |
| 2018-12-31 | $-1.76 | $3.44 | x |
| 2019-12-31 | $12.53 | $3.44 | x |
| 2020-12-31 | $6.77 | $3.44 | x |
| 2021-12-31 | $11.87 | $3.44 | x |
| 2022-12-31 | $4.74 | $3.44 | x |
| 2023-12-31 | $2.84 | $3.44 | x |
| 2024-12-31 | $1.18 | $3.44 | x |
| 2025-12-31 | $2.19 | $3.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Relmada Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -66.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-66.33%) is above the historical average (-121.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -106.11% | -151.77% | 0.43x | 1.62x | $-13.19K |
| 2013 | 0.00% | -877.66% | 0.00x | 0.00x | $5.48 Million |
| 2014 | -236.14% | 0.00% | 0.00x | 2.77x | $-21.68 Million |
| 2015 | -236.14% | 0.00% | 0.00x | 2.77x | $-21.68 Million |
| 2016 | -42.24% | 0.00% | 0.00x | 1.45x | $-3.68 Million |
| 2017 | -430.53% | 0.00% | 0.00x | 1.94x | $-6.43 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.41 Million |
| 2019 | -12.97% | 0.00% | 0.00x | 1.01x | $-26.57 Million |
| 2020 | -56.31% | 0.00% | 0.00x | 1.12x | $-70.01 Million |
| 2021 | -60.38% | 0.00% | 0.00x | 1.07x | $-146.58 Million |
| 2022 | -111.83% | 0.00% | 0.00x | 1.09x | $-171.09 Million |
| 2023 | -115.74% | 0.00% | 0.00x | 1.14x | $-107.33 Million |
| 2024 | -225.15% | 0.00% | 0.00x | 1.29x | $-83.53 Million |
| 2025 | -66.33% | 0.00% | 0.00x | 1.09x | $-66.04 Million |
Industry Comparison
This section compares Relmada Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $54,100,948
- Average return on equity (ROE) among peers: -38.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Relmada Therapeutics Inc (RLMD) | $218.73 Million | -106.11% | 0.08x | $360.82 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $31.35 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $99.10 Million | -22.07% | 0.12x | $260.76 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $106.02 Million | -68.71% | 0.36x | $847.89 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $27.72 Million |
| Abivax SA American Depositary Shares (ABVX) | $48.18 Million | -23.29% | 0.12x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.58 Billion |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more